12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nivolumab: Interim Phase Ib data

Interim data from 52 evaluable patients in an open-label, U.S. Phase Ib trial showed that concurrent dosing with Yervoy ipilimumab plus nivolumab led to an ORR of 40%. Specifically, 3 mg/kg Yervoy plus 0.3 mg/kg nivolumab led to an ORR of 21% (n=14); 3 mg/kg Yervoy plus 1 mg/kg nivolumab led to an ORR of 53% (n=17); 1 mg/kg Yervoy plus 3 mg/kg nivolumab led to an ORR of 40% (n=15); and 3 mg/kg Yervoy plus 3 mg/kg nivolumab led to an ORR of 50% (n=6). Additionally, 31% of all patients in the concurrent dosing arms experienced tumor shrinkage of >=80% at week...

Read the full 505 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >